The molecular pathogenesis of small cell lung cancer

Cancer Biology and Therapy

Volumn 10, Issue 1, 2010, Pages 1-10

  D'Angelo, Sandra P ^a   Pietanza, M Catherine ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chromosomes; Developmental pathways; Oncogenes; SCLC; Tumor suppressor genes; Tyrosine receptor kinases

Indexed keywords

CELL SURFACE MARKER; CISPLATIN; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; TYROSINE KINASE RECEPTOR;

CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; ONCOGENE; PATHOGENESIS; PROGNOSIS; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 77954405026     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.1.12045     Document Type: Review

References (119)

1. Krug LM, Kris MG, Rosenzweig K, Travis WD. Small Cell and Other Neuroendocrine Tumors of the Lung. In: Devita, Hellman & Rosenberg, ed. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott, Williams, and Wilkins, 2008.
2. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002; 21:6877-83.
3. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007; 2:327-43.
4. Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol 2003; 30:57-71. (Pubitemid 36254675)
5. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691-9. (Pubitemid 32492810)
6. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65:3497-508.
7. Ji L, Roth JA. Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 2008; 3:327-30.
8. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28:3-13. (Pubitemid 32730372)
9. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96:8489-92.
10. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000; 92:1303-7.
11. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87:895-902.
12. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11:1921-9.
13. Hyer JD, Silvestri G. Diagnosis and staging of lung cancer. Clin Chest Med 2000; 21:95-106.
14. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009; 18:687-94.
15. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24:3130-40.
16. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51.
17. Antonia S. Immunotherapy of extensive stage small cell lung cancer with dendritic cell based p53 vaccine: M17-02. Journal of Thoracic Oncology 2007; 2:198-9.
18. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54:73-87.
19. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007; 3:498-507.
20. Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A, Kaye FJ. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 2000; 19:4632-9.
21. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-607.
22. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42.
23. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008; 111:3322-30.
24. Zeitlin BD, Zeitlin IJ, Nor JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008; 26:4180-8.
25. Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer 2004; 6:113-22. (Pubitemid 39440209)
26. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27:6398-406.
27. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-37.
28. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60:6101-10.
29. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996; 15:31-40. (Pubitemid 26337007)
30. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68:2321-8.
31. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81.
32. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176-83.
33. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26:870-6.
34. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 1983; 34:779-87. (Pubitemid 13023348)
35. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982; 79:7837-41.
36. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79:7824-7.
37. Krystal G, Birrer M, Way J, Nau M, Sausville E, Thompson C, et al. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol 1988; 8:3373-81.
38. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993; 20:105-27.
39. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62.
40. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44.
41. Pal SK, Figlin RA, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer 2008; 9:340-5.
42. Shibata T, Kokubu A, Tsuta K, Hirohashi S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapyresistant lung cancer. Cancer Lett 2009; 283:203-11.
43. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998; 58:5239-47. (Pubitemid 28521188)
44. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1:913-22.
45. Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 2007; 33:391-406.
46. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009; 15:1277-87.
47. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2:1036-41.
48. Kotsakis AP. Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol 2009; 27:15.
49. Park GH, Plummer HK, 3rd, Krystal GW. Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. Blood 1998; 92:4138-49.
50. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol 2004; 31:106-11. (Pubitemid 38241028)
51. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19:3521-8.
52. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9:5880-7.
53. Spigel DR, Hainsworth JD, Simons L, Meng C, Burris HA, 3rd, Yardley DA, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007; 2:854-61.
54. Schneider BJ, Gadgeel S, Ramnath N, Worden FP, Wozniak A, Ruckdeschel J, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). J Clin Oncol (Meeting Abstracts) 2006; 24:17089.
55. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005; 103:2128-31.
56. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16:1811-6.
57. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63:6272-81. (Pubitemid 37255174)
58. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-7. (Pubitemid 34193985)
59. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007; 97:368-77.
60. Izycki T, Chyczewska E, Naumnik W, Ossolinska M. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol Res 2006; 16:49-54. (Pubitemid 44195050)
61. Bruchim I, Attias Z, Werner H. Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets 2009; 13:1179-92.
62. Yeh J, Litz J, Hauck P, Ludwig D, Krystal G. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. AACR Meeting Abstracts 2007; 2007:4396.
63. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004; 90:1825-9. (Pubitemid 38725660)
64. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 2004; 5:221-30.
65. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997; 18:26-45.
66. Ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1492-5. (Pubitemid 35340391)
67. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, et al. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 2001; 20:7658-67.
68. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 2006; 25:3078-88.
69. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009; 69:8645-51.
70. Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebocontrolled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007; 25:3945-51.
71. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009; 101:1049-57.
72. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004; 46:11-9.
73. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9:777-94.
74. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-60.
75. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 2005; 11:8789-98.
76. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27:6006-11.
77. Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, et al. Phase II trial of irinotecan, carboplatin and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009; 4:1555-60.
78. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278-84.
79. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90 - a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004; 151:1-44.
80. Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217:420-34.
81. Picard D, Khursheed B, Garabedian MJ, Fortin MG, Lindquist S, Yamamoto KR. Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature 1990; 348:166-8. (Pubitemid 120029065)
82. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002; 296:2232-5.
83. Zeng Y, Feng H, Graner MW, Katsanis E. Tumorderived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003; 101:4485-91.
84. Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, et al. Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res 2004; 10:8142-6.
85. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004; 9:881-8.
86. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 2009; 100:1415-24.
87. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008; 3:152-9.
88. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000; 60:3940-6. (Pubitemid 32204590)
89. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61:2945-52.
90. McDonald E, Workman P, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 2006; 6:1091-107.
91. Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006; 7:534-41. (Pubitemid 43891032)
92. Jensen M, Berthold F. Targeting the neural cell adhesion molecule in cancer. Cancer Lett 2007; 258:9-21.
93. Fossella FV. Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Proc Am Soc Clin Oncol 2002; 21.
94. Fossella FV. Phase II Trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. JCO 2005; 23.
95. Brezicka T, Bergman B, Olling S, Fredman P. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer 2000; 28:29-36.
96. Brezicka FT, Olling S, Bergman B, Berggren H, Engstrom CP, Hammarstrom S, et al. Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer. Tumour Biol 1992; 13:308-15.
97. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU. Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 1991; 139:297-304.
98. Lantuejoul S, Moro D, Michalides RJ, Brambilla C, Brambilla E. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998; 22:1267-76.
99. Livingston PO, Hood C, Krug LM, Ragupathi G. Antigen expression on SCLC cell lines confirms selection of a quadrivalent vaccine against SCLC containing GM2, fucosyl GM1, Globo H and polysialic acid. Proc Amer Assoc Cancer Res 2003.
100. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008; 26:2883-9.
101. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3:895-902. (Pubitemid 37500174)
102. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5:1026-33.
103. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001; 61:3200-5. (Pubitemid 32691976)
104. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol 2004; 14:357-64.
105. Liu H, Kho AT, Kohane IS, Sun Y. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med 2006; 3:232.
106. Watkins DN, Berman DM, Baylin SB. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003; 2:196-8.
107. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422:313-7.
108. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 2007; 12:535-42.
109. Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, Hayward D, et al. Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development 1996; 122:3765-73. (Pubitemid 27033873)
110. Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 1998; 9:583-9. (Pubitemid 128647238)
111. Weinmaster G. The ins and outs of notch signaling. Mol Cell Neurosci 1997; 9:91-102.
112. Ito T, Udaka N, Yazawa T, Okudela K, Hayashi H, Sudo T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000; 127:3913-21.
113. He BaJ DM. Wnt Signaling in Stem Cells and Lung Cancer. Ernst Schering Research Foundation Workshop 2006; 5:27-58.
114. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000; 11:273-82.
115. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003; 5:367-77.
116. Konigshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal? Am J Respir Cell Mol Biol 2010; 42:21-31.
117. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, Mengistab A, Finkbeiner W, Gallup M, et al. Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS One 2006; 1:93.
118. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003; 22:7218-21.
119. Ball DW. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 2004; 204:159-69.